Do Not Give Additional FFP
With an INR of 1.01 and ongoing bleeding, additional FFP transfusion is not indicated and will not provide hemostatic benefit. An INR of 1.01 is essentially normal, and further plasma administration will not meaningfully correct coagulation or stop the bleeding 1, 2.
Why FFP Won't Help at INR 1.01
Your patient's coagulation profile is already normalized. The evidence is clear on this point:
- FFP transfusion for INR ≤1.5 does not confer hemostatic benefit while unnecessarily exposing patients to transfusion risks 3
- Research demonstrates that FFP transfusion fails to reliably reduce INR when the baseline is <1.7, with only 50% of patients at INR 1.7 showing any significant change 1
- The mathematical relationship shows minimal INR change per FFP unit at near-normal values (INR change = 0.37 × pretransfusion INR - 0.47), meaning at INR 1.01 you would expect essentially zero effect 1
What You Should Do Instead
Look for the actual cause of bleeding:
- Platelet dysfunction or thrombocytopenia - Check platelet count and function; consider platelet transfusion if <50 × 10⁹/L in active bleeding
- Surgical/anatomical bleeding source - The bleeding is likely mechanical, not coagulopathic
- Antiplatelet agents - Aspirin, clopidogrel, NSAIDs can cause bleeding despite normal INR
- Uremia or liver dysfunction - Can impair hemostasis independent of INR
- Hypofibrinogenemia - Check fibrinogen level; consider cryoprecipitate or fibrinogen concentrate if <1.5-2.0 g/L 4
Guideline Support
The 2025 American College of Chest Physicians guidelines specifically address this scenario 5:
- For procedures, FFP is only suggested when targeting INR reduction from >2.0 down to 1.5-2.0 range
- There is no indication for FFP at INR 1.01
- The Association of Anaesthetists guidelines similarly state that abnormal coagulation tests are poor predictors of bleeding in stable patients, and prophylactic FFP use is not recommended 4
Risks of Unnecessary FFP
Continuing FFP transfusion at this INR exposes your patient to:
- Transfusion-related acute lung injury (TRALI)
- Transfusion-associated circulatory overload (TACO)
- Allergic/anaphylactic reactions (occurred in 14.5% in one study) 6
- Infectious disease transmission
- Unnecessary time delays in definitive management 6
Common Pitfall
The trap here is assuming that "3 units didn't work, so maybe 1 more will." The INR is already corrected. The bleeding has a different etiology that requires investigation and targeted intervention, not more plasma.